European Respiratory Journal

Article	Citations
Comparison of oronasal and nasal masks in home mechanical ventilation: an observational cohort and bench study	803
The 10-year temporal evolution of respiratory support and associated outcomes in extremely premature infants: betting on a favourable forecast for the next decade	542
Continuous Positive Airway Pressure and Mandibular Advancement Splints: The CHOICE Multi-center Open-Label Randomized Clinical Trial	433
Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies	314
Interstitial lung disease increases susceptibility to and severity of COVID-19	275
Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury	209
Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study	200
Generalizability of pharmaceutical randomized controlled trial eligibility criteria for progressive pulmonary fibrosis	167
Pulmonary gas exchange in relation to exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction	154
Can we call all obstructive lung diseases COPD?	153
Reply: Confounding in Mendelian randomisation studies	149
Defining trajectory in severe asthma: can it be changed?	137
From small to big, using microRNA profiling to investigate infant origins of childhood asthma	136
ERJPodcast August 2023: Simplifying pharmacotherapy for patients with COPD	130
Oxidation alters IL-33 function: new insights in the biology of different forms of IL-33 and their relevance for COPD	127
The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypes	116
More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice	115
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?	115
Endothelial to mesenchymal transition: a novel pathological feature of pulmonary fibrosis	109
Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics	107
Leukocyte telomere length: the dawn of a new era of personalised medicine in fibrotic interstitial lung diseases?	105
Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial	99
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	98
ERJPodcast November 2023: Children and the ERS	97
Local targeting of TSLP: feat or defeat	96

Reply: The concept and application of the treatable traits approach in interstitial lung disease and other chronic respiratory diseases	96
Bronchiectasis in low- and middle-income countries: the importance of the wider view	94
Pleuroparenchymal fibroelastosis: so many unmet needs	93
Chymase-1: a “MAST”-er switch in COPD?	92
Reconciling the past and considering the future of pulmonary function test interpretation	91
CXCL6 in idiopathic pulmonary fibrosis: a novel mediator in the complex epithelial–mesenchymal crosstalk	89
Early-life airway microbiome and childhood asthma development	89
Safety of early rehabilitation after acute pulmonary embolism	82
Advances in pleural diseases	80
Reply to: Sputum colour matters: haemoptysis in a bronchiectasis registry	79
10 pack-years of smoking: not the magic number for COPD risk and prognosis	79
Ethnicity corrections in pulmonary function test reports: what to do?	77
Reply: Guideline recommendations don't exist in a vacuum	76
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	72
Overweight and dysanapsis in childhood asthma	71
Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension	71
ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma	70
CD94+natural killer cells potentiate pulmonary ischaemia–reperfusion injury	69
Telerehabilitation: a key player in reducing the travel emissions cost of respiratory healthcare?	68
Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial	67
Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis	66
Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension	66
Missing airways, ventilation defects and conductive airway physiology in asthma	66
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment	65
COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy	65
Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls	63
Occupational inhalant exposures and longitudinal lung function decline	63
Accelerated decline in lung function in adults with a history of remitted childhood asthma	63
Predicting steroid responsiveness using airway smooth muscle in COPD: a HISTORIC study	62
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	62
Hiding in plain sight: the evolving definition of chronic breathlessness and new ICD-11 wording	61
Shorter duration of antibiotic therapy for exacerbation of COPD	61
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease	60
Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment	60
PD-L1highAT2 cells: a new player for alveoli regeneration	60
The transcriptomic landscape of diffuse radiological bronchiectasis	60
Gas exchange: the neglected piece in the PAH puzzle	59
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment	58
Bronchodilators in bronchiectasis: there is light but it is still too dim	58
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component	58
Interpreting blood eosinophil counts in health and obstructive lung disease	57
Addressing the effect of ancestry on lung volume	53
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing	52
ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (FENO50)	52
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	52
Clinical challenges in applying the new lung function test interpretive strategies: navigating pitfalls and possible solutions	51
Pulmonary phase contrast CT imaging: a novel setup at the Italian synchrotron for the study of fresh lungs at human scale	51
Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD	50
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	49
Host–microbial interactions differ with age of asthma onset	48

Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	48
Adult-onset idiopathic peripheral pulmonary artery stenosis	48
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness	47
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	47
Genome-wide association study of chronic sputum production implicates loci involved in mucus production and infection	47
Analyses of 1236 genotyped primary ciliary dyskinesia individuals identify regional clusters of distinct DNA variants and significant genotype–phenotype correlations	47
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	47
Endotypic traits of supine position and supine-predominant obstructive sleep apnoea in Asian patients	47
Lung function from school age to adulthood in primary ciliary dyskinesia	45
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	44
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)	44
Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea	44
The impact of outpatientversusinpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised clinical trial	44
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test	44
Lung allograft transbronchial cryobiopsy for critical ventilated patients: a randomised trial	43
Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial	42
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	42
Airway autoantibodies are determinants of asthma severity	42
Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?	42
Impact of COVID-19 social distancing measures on lung transplant recipients: decline in overall respiratory virus infections is associated with stabilisation of lung function	42
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study	41
The risk of community-acquired pneumonia in children using gastric acid suppressants	41
Reply to: Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?	41
The accuracy of forced vital capacity for diagnosing restrictive allograft syndrome and mixed phenotype of chronic lung allograft dysfunction	40
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis	40
Air pollution, SARS-CoV-2 incidence and COVID-19 mortality in Rome: a longitudinal study	40
The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories	40
Dietary intake of vitamin A, lung function and incident asthma in childhood	39
Reference equations for evaluation of spirometry function tests in South Asia, and among South Asians living in other countries	39
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	39
Feasibility of unsedated lung MRI in young children with cystic fibrosis	39
Reply to: Room for methodological improvement in gait speed study for COPD patients	38
An interferon-inducible signature of airway disease from blood gene expression profiling	38
Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism	38
Insights into the clinical outcomes of bronchiectasis	38
Repeatability of impulse oscillometry in patients with severe asthma	38
Cytokines as prognostic biomarkers in pulmonary arterial hypertension	38
Impact of the COVID-19 pandemic on influenza and respiratory syncytial virus antibody titres in the community: a prospective cohort study in Neustadt, Thuringia, Germany	38
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	37
Implications of the new ERS/ATS standards on the interpretation of lung function tests	37
Outcomes over the first two years of treatment with mepolizumab in severe asthma	37
Cigarette smoke augments CSF3 expression in neutrophils to compromise alveolar–capillary barrier function during influenza infection	37
Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis	37
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry	37
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease	36
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	36
Extended D-dimer cut-offs and machine learning for ruling out pulmonary embolism in individuals undergoing computed tomography pulmonary angiography	36
TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension	36
Real-world effectiveness of airway clearance techniques in children with cystic fibrosis	36
Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension	36
Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort	35
Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support	35
Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice	35
PET-CT-guidedversusCT-guided biopsy in suspected malignant pleural thickening: a randomised trial	35
Validating the Breathing Vigilance Questionnaire for use in dysfunctional breathing	35
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	35
The environmental impact of inhaled therapy: making informed treatment choices	35
Genome-wide association study of preserved ratio impaired spirometry (PRISm)	34
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint	34
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	34
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy	33
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model	33
Prognostic factors for development of acute respiratory distress syndrome following traumatic injury: a systematic review and meta-analysis	33
SARS-CoV-2 infections in people with primary ciliary dyskinesia: neither frequent, nor particularly severe	33
Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial	33
Physical activity, sedentary behaviour and incidence of obstructive sleep apnoea in three prospective US cohorts	33
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase	33
The antimicrobial peptide S100A8/A9 produced by airway epithelium functions as a potent and direct regulator of macrophage phenotype and function	33
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	32
Rothia mucilaginosais an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease	32
Dynamic lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction	32
Soluble VE-cadherin: not just a marker of endothelial permeability	32
Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19	32
The potential and challenges of radiomics in uncovering prognostic and molecular differences in interstitial lung disease associated with systemic sclerosis	31
Same-day repeatability of fractional exhaled nitric oxide in severe asthma	31
Methionine supplementation: potential for improving alveolar macrophage function through reverse cholesterol transport?	31
Biomarker signatures for progressive idiopathic pulmonary fibrosis	31
A randomised controlled trial of intrapleural balloon intercostal chest drains to prevent drain displacement	31
Tuberculosis and COVID-19 co-infection: description of the global cohort	31
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence	31

Reply: Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?	31
Comparison of the treatment guidelines for sarcoidosis: common sense in the search for evidence	30
The coexistence of asthma and COPD: some considerations about prevalence and lung function decline	30
Quantitative texture-based analysis of pulmonary parenchymal features on chest CT: comparison with densitometric indices and short-term effect of changes in smoking habit	29
Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling	29
Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection	29
Aspergillustracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study	29
Improved prediction of asthma exacerbations by measuring distal airway inflammation	29
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	28
Reply: Is high-dose glucocorticoid beneficial in COVID-19?	28
Referral criteria to palliative care for patients with respiratory disease: a systematic review	28
Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis	28
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry	28
Ethical obligations for supporting healthcare workers during the COVID-19 pandemic	28
Genome-wide association study in patients with pulmonaryMycobacterium aviumcomplex disease	28
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	28
U-BIOPRED/BIOAIR proteins: inflammation or infection?	28
Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19	28
Reply: BAL lymphocyte percentage is as good as the company it keeps	27
Reduction in asthma admissions during the COVID-19 pandemic: consequence of public health measures in Singapore	27
Asthma-related sudden death in athletes: a retrospective analysis of the US NCCSIR database (1982–2018)	27
Transthoracic shear wave ultrasound: a noninvasive tool to differentiate between benign and malignant subpleural lung lesions	27
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital	27
Recommendations for respiratory syncytial virus surveillance at the national level	27
Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?	27
Similarity network fusion for the integration of multi-omics and microbiomes in respiratory disease	27
Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting	27
A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity	27
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?	26
Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic	26
Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	26
Respiratory effort and hypertension in obstructive sleep apnoea	26
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization	26
Antibiotics for asthma attacks: masking uncertainty	26
Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism	26
Obstructive sleep apnoea, nocturnal hypoxaemia, and cognitive decline in elderly patients	26
It is time to optimise the management of latent tuberculosis infection in children	26
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	26
The right ventricle tamed	26
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate us	25
Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials	25
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	25
Dysfunctional breathing after COVID-19: recognition and ramifications	25
Transbronchial cryobiopsy: the right procedure for the right patient in the right place at the right time	25
COPD detection in lung cancer screening programmes: “hitting two birds with one stone”	25
Lung cancer in pulmonary fibrosis: no room for nihilism!	25
The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series	25
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	25
ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction	24
Effect of highversuslow dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial	24
Heterogeneity of treatment response in bronchiectasis clinical trials	24
The lung that rules the heart	24
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	24
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	24
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	24
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis	24
Asthma and cardiovascular disease: embracing disease heterogeneity is required	24
European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis	24
Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond	24
A breath of the future: a novel human model for COPD and beyond	23
Detection ofM. tuberculosisDNA in peripheral blood mononuclear cells of tuberculosis contacts does not associate with blood RNA signatures for incipient tuberculosis	23
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)	23
Reply to: Is there a kindling effect in COPD exacerbations?	23
Casting a wider net for tuberculosis cases	23
Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia	23
Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control	23
Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study	23
Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	23
Age, host response, and mortality in COVID-19	22
Lung function and cardiovascular disease: a two-sample Mendelian randomisation study	22
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	22
Association between the use of statins and risk of interstitial lung disease/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data	22
Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease: a randomised, double-blind, placebo-controlled, crossover trial	22
Asthma remission: what is it and how can it be achieved?	22
Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study	22
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	22
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond	22
Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia	22
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma	22
Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children	22
Socioeconomic biases in asthma control and specialist referral of possible severe asthma	22
The discovAIR project: a roadmap towards the Human Lung Cell Atlas	22
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	22
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors	22
“Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial.” D. Sto	21
Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity	21
The blood transcriptional response in patients developing intensive care unit-acquired pneumonia	21
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnea	21
Is long COVID an autoimmune disease?	21
Interstitial lung abnormalities are associated with decreased mean telomere length	21
“Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.” F. Torres,	21
Inhaled soluble guanylate cyclase stimulator for the treatment of pulmonary arterial hypertension: struggling to breathe easy	21
Emergence of bedaquiline resistance in a high tuberculosis burden country	21
“International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.” Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek,et al. Eur Respir J2014; 43: 343–373.	21
“Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.” A. Jouet, C. Gaudin, N. Badalato,et al.Eur Respir J2021; 57: 2002338.	21